Kymera Therapeutics used its presentation at the H.C. Wainwright 28th Annual Global Investment Conference on Sept. 14, 2026, to outline progress in its oral drug programs and clinical timeline. Chief Financial Officer Bruce Jacobs said the company marked its 10-year anniversary and has advanced seven molecules into clinical development since founding in 2016.
Kymera’s wholly owned oral STAT6 degrader KT-621 is being developed for atopic dermatitis and asthma. The company cited an estimated 6 million to 9 million U.S. patients with moderate-to-severe atopic dermatitis, of whom about 400,000 are currently receiving advanced systemic therapies. Jacobs said KT-621 data from a four-week study of 22 patients showed 95% to 98% target elimination in blood and skin, and characterized the results as generally in line with, and in some cases numerically superior to, dupilumab, the injectable biologic from Sanofi and Regeneron.
Dupixent generates more than $20 billion in annual sales and is approved in eight or nine indications, including atopic dermatitis, asthma, COPD and eosinophilic esophagitis.
Kymera completed enrollment in June 2026 for the Phase IIb BROADEN2 trial in atopic dermatitis and expects to report data before the end of 2026. A Phase III study in atopic dermatitis is anticipated to begin in mid-2027, pending data and FDA support. The company also expects to announce a new development candidate in early 2027, a timing shift from 2026 due to pipeline activity, and to report Phase IIb BREADTH asthma data before the end of 2027.
Kymera has partnered programs, including an IRAK4 program with Sanofi and a CDK2 molecular glue program with Gilead. The company estimates total milestone payments of about $2 billion across the Sanofi and Gilead partnerships over time.
Jacobs said Kymera’s current ratio is above 10, indicating liquid assets exceed short-term obligations. Wall Street analysts have consensus price targets for KYMR between $111 and $180. He described target selection as focused on proteins that are inaccessible or poorly drugged, where targeted protein degradation may be the best or only solution, and called KT-621 a once-in-a-generation biotech market opportunity.
